If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The update promises to revolutionize laboratory workflows by optimizing resources
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The expansion includes a larger technical and service team and increased local procurement
Subscribe To Our Newsletter & Stay Updated
